Do analysts rate AVIR or BMEA?

Biomea Fusion has a consensus target price of $8.50, suggesting a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, AVIR or BMEA?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is AVIR or BMEA more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Biomea Fusion N/A -265.37% -103.96%

Does the media refer more to AVIR or BMEA?

In the previous week, Biomea Fusion had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.80 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRLD or BMEA more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Biomea Fusion N/A -265.37% -103.96%

Does the media favor PRLD or BMEA?

In the previous week, Biomea Fusion had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.80 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XFOR or BMEA?

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for X4 Pharmaceuticals and 4 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.80 beat X4 Pharmaceuticals' score of 0.63 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BMEA or HELP?

Biomea Fusion is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Cybin N/A N/A -$148M -$4.23 N/A

Is BMEA or HELP more profitable?

Cybin's return on equity of -68.27% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Cybin N/A -68.27% -58.26%

Does the media refer more to BMEA or HELP?

In the previous week, Cybin had 12 more articles in the media than Biomea Fusion. MarketBeat recorded 16 mentions for Cybin and 4 mentions for Biomea Fusion. Cybin's average media sentiment score of 1.01 beat Biomea Fusion's score of 0.80 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMEA or ELYM?

Biomea Fusion currently has a consensus price target of $8.50, suggesting a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, BMEA or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is BMEA or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Eliem Therapeutics N/A -47.03% -45.97%

Does the media refer more to BMEA or ELYM?

In the previous week, Biomea Fusion had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 1 mentions for Eliem Therapeutics. Biomea Fusion's average media sentiment score of 0.80 beat Eliem Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eliem Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biomea Fusion (BMEA) Competitors

$1.31 -0.02 (-1.65%)

As of 03:09 PM Eastern

Compare

BMEA vs. AVIR, PRLD, XFOR, HELP, and ELYM

Should you buy Biomea Fusion stock or one of its competitors? MarketBeat compares Biomea Fusion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomea Fusion include Atea Pharmaceuticals (AVIR), Prelude Therapeutics (PRLD), X4 Pharmaceuticals (XFOR), Cybin (HELP), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.

How does Biomea Fusion compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Atea Pharmaceuticals' return on equity of -57.01% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion has a consensus target price of $8.50, suggesting a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

In the previous week, Biomea Fusion had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.80 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biomea Fusion beats Atea Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Prelude Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Prelude Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 74.44%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biomea Fusion has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.83	-$99.50M	-$1.00	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Prelude Therapeutics' return on equity of -118.24% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Biomea Fusion	N/A	-265.37%	-103.96%

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biomea Fusion had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.80 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biomea Fusion beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for X4 Pharmaceuticals and 4 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.80 beat X4 Pharmaceuticals' score of 0.63 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Biomea Fusion has lower revenue, but higher earnings than X4 Pharmaceuticals. Biomea Fusion is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.03	-$79.20M	-$4.54	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

X4 Pharmaceuticals currently has a consensus price target of $9.70, suggesting a potential upside of 136.30%. Biomea Fusion has a consensus price target of $8.50, suggesting a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

X4 Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market.

Biomea Fusion has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Biomea Fusion	N/A	-265.37%	-103.96%

Summary

Biomea Fusion beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Cybin?

Biomea Fusion (NASDAQ:BMEA) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Biomea Fusion presently has a consensus target price of $8.50, suggesting a potential upside of 550.84%. Cybin has a consensus target price of $55.00, suggesting a potential upside of 715.66%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cybin	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cybin's return on equity of -68.27% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Cybin	N/A	-68.27%	-58.26%

In the previous week, Cybin had 12 more articles in the media than Biomea Fusion. MarketBeat recorded 16 mentions for Cybin and 4 mentions for Biomea Fusion. Cybin's average media sentiment score of 1.01 beat Biomea Fusion's score of 0.80 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, Cybin has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

Cybin beats Biomea Fusion on 9 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Eliem Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biomea Fusion currently has a consensus price target of $8.50, suggesting a potential upside of 550.84%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Biomea Fusion had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 1 mentions for Eliem Therapeutics. Biomea Fusion's average media sentiment score of 0.80 beat Eliem Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eliem Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eliem Therapeutics' return on equity of -47.03% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the broader market.

Summary

Biomea Fusion beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$94.35M	$3.64B	$6.74B	$12.55B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.92	21.16	27.01	24.38
Price / Sales	N/A	311.48	585.49	117.90
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.11	8.59	10.85	6.35
Net Income	-$61.80M	$23.83M	$3.58B	$330.89M
7 Day Performance	-6.57%	-3.21%	-2.09%	-0.97%
1 Month Performance	11.79%	6.65%	3.29%	-0.36%
1 Year Performance	-32.58%	49.04%	26.51%	20.00%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	2.7275 of 5 stars	$1.31 -1.8%	$8.50 +550.8%	-33.5%	$94.35M	N/A	N/A	50	News Coverage
AVIR Atea Pharmaceuticals	0.7553 of 5 stars	$4.87 -2.2%	N/A	+29.2%	$398.54M	N/A	N/A	70	News Coverage
PRLD Prelude Therapeutics	3.8289 of 5 stars	$4.99 +1.6%	$7.67 +53.6%	+445.0%	$391.06M	$12.14M	N/A	120	News Coverage
XFOR X4 Pharmaceuticals	2.9953 of 5 stars	$4.03 -2.4%	$9.38 +132.6%	+183.2%	$389.54M	$35.11M	N/A	80	News Coverage
HELP Cybin	2.9757 of 5 stars	$5.89 -5.6%	$58.75 +897.5%	N/A	$386.78M	N/A	N/A	50	Positive News Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. AVIR, PRLD, XFOR, HELP, and ELYM

How does Biomea Fusion compare to Atea Pharmaceuticals?

Summary

How does Biomea Fusion compare to Prelude Therapeutics?

Summary

How does Biomea Fusion compare to X4 Pharmaceuticals?

Summary

How does Biomea Fusion compare to Cybin?

Summary

How does Biomea Fusion compare to Eliem Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. AVIR, PRLD, XFOR, HELP, and ELYM

How does Biomea Fusion compare to Atea Pharmaceuticals?

Is AVIR or BMEA more profitable?

Do analysts rate AVIR or BMEA?

Do institutionals & insiders believe in AVIR or BMEA?

Which has more risk and volatility, AVIR or BMEA?

Which has preferable valuation & earnings, AVIR or BMEA?

Does the media refer more to AVIR or BMEA?

Summary

How does Biomea Fusion compare to Prelude Therapeutics?

Which has more risk & volatility, PRLD or BMEA?

Do analysts prefer PRLD or BMEA?

Which has higher earnings and valuation, PRLD or BMEA?

Is PRLD or BMEA more profitable?

Do insiders & institutionals believe in PRLD or BMEA?

Does the media favor PRLD or BMEA?

Summary

How does Biomea Fusion compare to X4 Pharmaceuticals?

Does the media refer more to XFOR or BMEA?

Do insiders & institutionals hold more shares of XFOR or BMEA?

Which has higher earnings and valuation, XFOR or BMEA?

Do analysts prefer XFOR or BMEA?

Which has more risk & volatility, XFOR or BMEA?

Is XFOR or BMEA more profitable?

Summary

How does Biomea Fusion compare to Cybin?

Do analysts recommend BMEA or HELP?

Do institutionals and insiders have more ownership in BMEA or HELP?

Is BMEA or HELP more profitable?

Does the media refer more to BMEA or HELP?

Which has stronger earnings & valuation, BMEA or HELP?

Which has more volatility and risk, BMEA or HELP?

Summary

How does Biomea Fusion compare to Eliem Therapeutics?

Do institutionals and insiders hold more shares of BMEA or ELYM?

Do analysts recommend BMEA or ELYM?

Which has stronger valuation and earnings, BMEA or ELYM?

Does the media refer more to BMEA or ELYM?

Is BMEA or ELYM more profitable?

Which has more volatility and risk, BMEA or ELYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools